1. 1) 首相官邸．知的財産戦略本部．構想委員会．厚生労働省が進めるデータヘルス改革．2020．［https://www.kantei.go.jp/jp/singi/titeki2/tyousakai/kousou/2020/dai3/siryou4.pdf (accessed 2023-8-16) ］
2. 2) U.S. Department of Health and Human Services Food and Drug Administration. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products. Guidance for Industry. (September, 2022). ［https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products (accessed 2023-8-16) ］
3. 3) U.S. Department of Health and Human Services Food and Drug Administration. Real-World Data： Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance for Industry. (September, 2021). ［https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory (accessed 2023-8-16) ］
4. 4) U.S. Department of Health and Human Services Food and Drug Administration. Data Standards for Drug and Biological Product Submissions Containing Real-World Data, Draft Guidance for Industry. （October, 2021）. ［https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data (accessed 2023-8-16）］
5. 5) U.S. Department of Health and Human Services Food and Drug Administration. Real-World Data： Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products. Draft Guidance for Industry. （November, 2021）. ［https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products (accessed 2023-8-16）］